Clinical and pathological features of B-cell non-Hodgkin lymphomas lacking the surface expression of immunoglobulin light chains
| Autor: | Hiroshi Kawada, Y Tanaka, Miharu Yabe, Satomi Asai, Naoya Nakamura, Hayato Miyachi, Anar Damdinsuren, Daisuke Ohgiya, Yumiko Tanaka, Kiyoshi Ando, Yoshiaki Ogawa, Hiromichi Matsushita |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Pathology medicine.medical_specialty Clinical Biochemistry Antineoplastic Agents Kaplan-Meier Estimate Immunoglobulin light chain Disease-Free Survival Antibodies Monoclonal Murine-Derived immune system diseases hemic and lymphatic diseases medicine Humans Stage (cooking) B cell Aged Neoplasm Staging Retrospective Studies Aged 80 and over biology L-Lactate Dehydrogenase business.industry Lymphoma Non-Hodgkin Biochemistry (medical) General Medicine Middle Aged medicine.disease Flow Cytometry Lymphoma medicine.anatomical_structure Karyotyping Monoclonal Immunology biology.protein Rituximab Female Immunoglobulin Light Chains Lymphoma Large B-Cell Diffuse Antibody business Diffuse large B-cell lymphoma medicine.drug |
| Zdroj: | Clinical chemistry and laboratory medicine. 50(9) |
| ISSN: | 1437-4331 |
| Popis: | The flow cytometric analysis of surface immunoglobulin light chains (sIgL) is used as a simple method for evaluating monoclonal B-cell proliferation. However, the sIgL expression, κ or λ, is occasionally undetectable in cases with B-cell non-Hodgkin lymphomas (B-NHL). The purpose of this study was to investigate the clinical and pathological characteristics of these B-NHL cases.We retrospectively analyzed 50 cases with previously untreated sIgL-negative B-NHL. All of these cases had been diagnosed at Tokai University Hospital between January 2001 and February 2011. Their medical charts were reviewed.These cases had several clinical features: diffuse large B-cell lymphoma (DLBCL) (72%), a high serum lactate dehydrogenase level (66%), clinical stage III and IV (68%), and complex karyotypes (58%). Seven out of eight evaluated patients (87%) did not express cytoplasmic IgL, and the DNA rearrangement pattern of IgL showed diversity in 10 analyzed patients. The 5-year event-free survival of all the sIgL-negative B-NHL cases was significantly better with rituximab-containing chemotherapies in comparison to the regimens without it (57.9% vs. 17.9%, p=0.0207), although there was no statistical significance when the DLBCL cases were analyzed (56.6% vs. 22.2%, p=0.1530).These findings suggest that sIgL-negative B-NHL cases predominantly developed DLBCL in advanced disease, but were heterogeneous at the molecular level. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|